Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BioZak Japan Established to Supply Mfg. Technology on Hepatitis C Agents
December 17, 2001
- Fukuda Denshi to Manufacture ECG in China
December 17, 2001
- Eli Lilly, Chugai to Dissolve Their JV
December 17, 2001
- Hitachi Medical Develops Lung Cancer Diagnosis Support System
December 17, 2001
- EPS: CRO, SMO Businesses Boost Sales by 42.2%
December 17, 2001
- ISI Provides Medical, Pharmaceutical Literature Search Services
December 17, 2001
- AstraZeneca to Launch New Corticosteroid Inhaler, Pulmicort Turbuhaler
December 17, 2001
- JAPANESE LANGUAGE BOOKS
December 17, 2001
- Differences in Culture Prevent Tanabe, Taisho from Getting Together
December 17, 2001
- Chugai to Become Member of Roche Group
December 17, 2001
- BUSINESS NEWS IN BRIEF
December 17, 2001
- Actelion Sets Up Japanese Subsidiary with 2 ERAs: Dr Widmann
December 17, 2001
- Combined Sales of 12 Major Wholesalers Up 15.7%, Net Profits Down 50.2%
December 17, 2001
- Mean Price Discrepancy Rate Is 7.1%: Drug Price Survey
December 17, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
December 17, 2001
- Latest Proposals for NHI Price System Reform Explained
December 17, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 17, 2001
- Employees' Copayment to Be Raised to 30% "When Necessary"
December 17, 2001
- REGULATORY NEWS IN BRIEF
December 10, 2001
- Fujisawa Hopes to Become Global Megaplayer by 2010: President Aoki
December 10, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…